May 17, 2020

Selexys Pharma completes $23 mln Series A equity financing

completion of Phase 2 clinical study
frequent hospitalizati
Admin
2 min
Selexys Pharma completes $23 mln Series A equity financing
Selexys Pharmaceuticals, Corp said it has completed $23 million Series A equity financing, led by MPM Capital. It has also entered into an agreement wi...

Selexys Pharmaceuticals, Corp said it has completed $23 million Series A equity financing, led by MPM Capital.

It has also entered into an agreement with Novartis Pharmaceuticals, whereby Novartis has been granted an exclusive option to buy Selexys and its lead asset, the anti-P-selectin antibody SelG1, post successful completion of Phase 2 clinical study in patients with sickle cell disease. This also includes the upfront, acquisition and milestone payments.

The agreement with Novartis could reach up to $665 million, the news reports said.

Dr. Scott Rollins, President and CEO of Selexys said, “Patients with sickle cell disease endure great suffering and frequent hospitalization due to painful vasocclusive crisis. Chronic blockade of P-selectin function with SelG may improve clinical outcomes and lower the associated cost of patient care.” He also said, “We are excited to welcome MPM and Novartis and look forward to a productive partnership.”

The combination of the Novartis agreement and the closing of the Series A financing will allow Selexys to advance the SelG1 program through a large Phase 2 clinical study in sickle cells patients and will also fund a second program at Selexys, an anti-PSGL-1 antibody through a Phase 1 clinical study.

Selexys Pharmaceuticals is a privately held biopharmaceutical company that focuses on development of therapeutics for treating inflammation, thrombosis, and metastasis across a broad range of diseases. MPM Capital is the world’s largest life science-dedicated venture investors.

Share article

Jun 17, 2021

Dexcom: changing the lives of people with type 1 diabetes

diabetes
glucosemonitoring
type1diabetes
insulin
3 min
British actress Nina Wadia OBE tells us how her son's life has changed since using glucose monitoring system Dexcom

It is estimated that 9.3% of adults around the world are living with type 1 diabetes, which amounts to a total of 463 million people. A further 1.1 million children and adolescents under the age of 20 are living with the condition. 

Unlike the more prevalent type 2 diabetes, where the body still produces insulin and symptoms develop slowly, people with type 1 diabetes need regular insulin injections or pumps, and must monitor their sugar levels frequently. 

In recent years a number of remote glucose monitoring systems have become available that patients can use at home. These work with a sensor, usually placed under the skin, that measures glucose levels every few minutes. This information is then transmitted wirelessly to a device like a smartphone or tablet, which can then be shared with their clinician. 

British actress Nina Wadia's son Aidan, 14, has type 1 diabetes, and has been managing his condition using Dexcom, a glucose monitoring system used by patients all over the world. Here Wadia explains how Dexcom has improved their lives. 

As a parent of someone with type 1 diabetes, what is your day-to-day life like?
Being able to take a breath, think and pivot constantly without getting frustrated becomes an essential mindset because sometimes it feels like each day is determined to be different from the day before. Whatever worked yesterday is going to misfire today. 

Which areas of yours and Aidan’s life are most impacted by diabetes? 
The one thing that you have to fight hard to reclaim is spontaneity, especially when it comes to food and exercise. It’s only when this is taken do you realise how essential each one is. You can be flexible and there are no real limits, but only in the sense that a great athlete can be flexible without limits because they’ve trained super hard to be that way. So we’ve all had to become athletes when it comes to being spontaneous.

How has Dexcom helped you and Aidan? 
Dexcom has brought future science fiction to real life today. The continuous glucose monitoring system is tiny, sits discreetly on his body and gives him a ten-day breather between sensor changes, so it's goodbye finger-pricking seven times daily. 

Dexcom is totally active at a grass roots level and for Diabetes Awareness has pledged to donate £2,000 if #DexcomDiabetesStories and/or #DexcomWarriorStories is shared 200 times! I’ll be sharing more on social media and would love to hear how other families are winning their fights.

Maybe most importantly Dexcom is trying to introduce a reimbursement programme for type 1 diabetes  patients which will give greater access to modern, life changing hi-tech. I want to spread the word on the importance of accessing it through this campaign. 

If you compared your life today with how it was before Aidan was using Dexcom, what has changed? 
It's always working, which lets him take his mind off diabetes for longer stretches. It also lets me get off his back. We both receive alerts so I no longer have to pester him by asking him what his number is, and especially importantly, I don’t have to wake him at night to prick his finger if I’m worried. Dexcom gave us back our sleep!

Share article